Human CXCL5/ENA-78 Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB2541

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
MAB2541
MAB2541-SP
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Validated by

Biological Validation

Species Reactivity

Human

Applications

Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 33103

View all CXCL5/ENA-78 Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant human CXCL5/ENA-78
Ala37-Asn114
Accession # P42830

Specificity

Detects human CXCL5/ENA‑78 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human CXCL1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 16, recombinant mouse CXCL1, 2, 4, 6, 7, 9, 10, 11, 12, 15, 16, recombinant rat CXCL5, and recombinant porcine CXCL8 is observed.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for Human CXCL5/ENA-78 Antibody

Detection of Human CXCL5/ENA-78 antibody by Western Blot.

Detection of Human CXCL5/ENA‑78 by Western Blot.

Western blot shows lysates of conditioned media (CM) and lysates from A549 human lung carcinoma cell line untreated (-) or treated (+) with human IL-1 beta for 24 hours. PVDF membrane was probed with 2 µg/mL of Mouse Anti-Human CXCL5/ENA-78 Monoclonal Antibody (Catalog # MAB2541) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for CXCL5/ENA-78 at approximately 10 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Applications for Human CXCL5/ENA-78 Antibody

Application
Recommended Usage

Western Blot

2 µg/mL
Sample: Conditioned media from A549 human lung carcinoma cell line treated with human IL-1 beta

Formulation, Preparation, and Storage

Purification

Protein A or G purified from ascites

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL5/ENA-78

CXCL5, also known as epithelial cell-derived neutrophil-activating peptide (ENA-78), is an 8 kDa proinflammatory member of the CXC subfamily of chemokines. Its Glu-Leu-Arg (ELR) motif confers angiogenic properties and distinguishes it from ELR-CXC chemokines which are angiostatic (1‑3). Human CXCL5 shares 57% amino acid (aa) sequence identity with mouse and rat CXCL5. Among other human ELR+ chemokines, it shares 77% aa sequence identity with CXCL6/GCP-2 and 35%‑51% with CXCL1/GRO alpha, CXCL2/GRO beta, CXCL3/GRO gamma, CXCL7/NAP-2, and CXCL8/IL-8. Inflammatory stimulation upregulates CXCL5 production in multiple hematopoietic cell types, fibroblasts, endothelial cells, and vascular smooth muscle cells. In vivo, CXCL5 is elevated at sites of inflammation and pulmonary fibrosis where it promotes neutrophil infiltration and activation as well as angiogenesis (3‑6). Its upregulation contributes to increased vascularization, tumor growth, and metastasis in many cancers (6‑9). Full length CXCL5 (78 aa) is trimmed at the N-terminus by cathepsin G and chymotrypsin to ENA-74 (74 aa) and ENA-70 (70 aa), with the shortened forms showing increased potency relative to full length CXCL5 (10, 11). CXCL5 exerts its effects primarily through interactions with CXCR2 (6, 12). It also binds duffy antigen receptor for chemokines (DARC), which can limit CXCR2-mediated responses (13, 14).

References

  1. Strieter, R.M. et al. (2005) Cytokine Growth Factor Rev. 16:593.
  2. Balestrieri, M.L. et al. (2008) Cardiovasc. Res. 78:250.
  3. Walz, A.. et al. (1991) J. Exp. Med. 174:1355.
  4. Strieter, R.M. et al. (1992) Immunol. Invest. 21:549.
  5. Koch, A.E. et al. (1994) J. Clin. Invest. 94:1012.
  6. Begley, L.A. et al. (2008) Neoplasia 10:244.
  7. Vandercappellen, J. et al. (2008) Cancer Lett. 267:226.
  8. Arenberg, D.A. et al. (1998) J. Clin. Invest. 102:465.
  9. Miyazaki, H. et al. (2006) Cancer Res. 66:4279.
  10. Wuyts, A. et al. (1999) Eur. J. Biochem. 260:421.
  11. Nufer, O. et al. (1999) Biochemistry 38:636.
  12. Ahuja, S.K. and P.M. Murphy (1996) J. Biol. Chem. 271:20545.
  13. Kashiwazaki, M. et al. (2003) Int. Immunol. 15:1219.
  14. Horton, L.W. et al. (2007) Cancer Res. 67:9791.

Alternate Names

CXCL5, ENA-78, ENA78

Entrez Gene IDs

6374 (Human)

Gene Symbol

CXCL5

UniProt

P42830

Additional CXCL5/ENA-78 Products

Product Documents for Human CXCL5/ENA-78 Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human CXCL5/ENA-78 Antibody

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.